The combination of vidutolimod and nivolumab demonstrated activity in a phase 2 trial of patients with high-risk, resectable melanoma, according to researchers. They reported these findings in Cancer Cell.
Clinical Trials
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy.
Longer Time Until Recurrence Associated With Better Melanoma Outcomes
An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved progression and survival.
Microbiotica initiates subject dosing in Phase Ib melanoma therapy trial
Microbiotica has dosed the first subject in the Phase Ib MELODY-1 clinical trial of MB097, a precision microbiome co-therapy targeting advanced melanoma.